Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.37 |
| ▸ | ACACB | O00763 | 1/20 | 0.36 |
| ▸ | ACACA | Q13085 | 1/20 | 0.36 |
| ▸ | SYK | P43405 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | HTR1B | P28222 | 1/20 | 0.36 |
| ▸ | HTR1F | P30939 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19641915 | 0.86 | NR3C2 (0.39) | MAPTCACNA1HSYKHTR1AHTR1B | |
| SCHEMBL19207287 | 0.84 | MAPT (0.41) | TP53MAPTADORA3ADORA2ASCN9A | |
| SCHEMBL19207316 | 0.83 | PDE4D (0.40) | HPGDSTP53MAPTCACNA1HACACB | |
| SCHEMBL19207284 | 0.83 | MAPT (0.40) | TP53MAPTADORA3ADORA2ASCN9A | |
| SCHEMBL19207291 | 0.82 | TP53 (0.41) | TP53MAPTADORA3ADORA2ASCN9A | |
| SCHEMBL19207322 | 0.82 | LMNA (0.39) | TP53MAPTADORA3ADORA2ASCN9A | |
| SCHEMBL21523997 | 0.80 | MAPK14 (0.34) | SCN9AHSD17B10PIK3CDNR3C2CSNK1D | |
| SCHEMBL19207351 | 0.79 | MAPT (0.37) | TP53MAPTADORA3ADORA2ASCN9A | |
| SCHEMBL19207254 | 0.78 | HPGDS (0.39) | HPGDSTP53MAPTACACBACACA | |
| SCHEMBL19207321 | 0.77 | HPGDS (0.38) | HPGDSTP53MAPTACACBACACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108473462-B | Pyrazole-pyridine derivatives as EAAT3 inhibitors | 豪夫迈·罗氏有限公司 | 2021-06-22 | — | — | CN | claimed |
| EP-3411365-B1 | PYRAZOL-PYRIDINE DERIVATIVES AS EAAT3 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2019-11-20 | — | — | EP | claimed |
| US-10457663-B2 | Pyrazol-pyridine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2019-10-29 | — | — | US | claimed |
| EP-3411365-A1 | PYRAZOL-PYRIDINE DERIVATIVES AS EAAT3 INHIBITORS | H. Hoffnabb-La Roche Ag (CH) | 2018-12-12 | — | — | EP | claimed |
| US-20180339975-A1 | PYRAZOL-PYRIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2018-11-29 | — | — | US | claimed |
| WO-2017133990-A1 | PYRAZOL-PYRIDINE DERIVATIVES AS EAAT3 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2017-08-10 | — | — | WO | claimed |
| CN-108473462-B | Pyrazole-pyridine derivatives as EAAT3 inhibitors | 豪夫迈·罗氏有限公司 | 2021-06-22 | — | — | CN | disclosed |
| EP-3411365-B1 | PYRAZOL-PYRIDINE DERIVATIVES AS EAAT3 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2019-11-20 | — | — | EP | disclosed |
| EP-3411365-B1 | PYRAZOL-PYRIDINE DERIVATIVES AS EAAT3 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2019-11-20 | — | — | EP | disclosed |
| US-10457663-B2 | Pyrazol-pyridine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2019-10-29 | — | — | US | disclosed |
| US-10457663-B2 | Pyrazol-pyridine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2019-10-29 | — | — | US | disclosed |
| EP-3411365-A1 | PYRAZOL-PYRIDINE DERIVATIVES AS EAAT3 INHIBITORS | H. Hoffnabb-La Roche Ag (CH) | 2018-12-12 | — | — | EP | disclosed |
| US-20180339975-A1 | PYRAZOL-PYRIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2018-11-29 | — | — | US | disclosed |
| WO-2017133990-A1 | PYRAZOL-PYRIDINE DERIVATIVES AS EAAT3 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2017-08-10 | — | — | WO | disclosed |
| WO-2017133990-A1 | PYRAZOL-PYRIDINE DERIVATIVES AS EAAT3 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2017-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10457663-B2 | Pyrazol-pyridine derivatives | MC3R, MC2R, DRD3 | HPGDS 4124/4885TP53 3140/4885MAPT 1613/4885 |
| US-20180339975-A1 | PYRAZOL-PYRIDINE DERIVATIVES | MC3R, MC2R, DRD3 | HPGDS 4124/4885TP53 3140/4885MAPT 1613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.